Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Scribe Therapeutics is a molecular engineering company focused on creating a new era of CRISPR-based genetic medicines. By pioneering its 'CRISPR by Design™' platform, Scribe aims to develop therapies that are safer, more effective, and can be delivered to a broader range of tissues and cell types. The company is dedicated to engineering custom X-Editing (XE) molecules for in vivo applications, tackling diseases with significant unmet medical needs and striving to move the entire field of genetic medicine forward.
Primary hub for research and development of CRISPR-based genetic medicines, molecular engineering, corporate operations, and strategic partnerships.
State-of-the-art laboratory and office space spanning approximately 132,000 square feet, custom-designed to support advanced molecular engineering, therapeutic development, and collaborative research.
Scribe Therapeutics fosters a dynamic, science-driven, and innovative work environment. The culture emphasizes collaboration, rigorous scientific inquiry, and a shared mission to develop transformative therapies for patients. Employees are encouraged to be pioneers in their respective fields.
The Alameda headquarters represents a significant investment in Scribe's growth, enabling the company to scale its research, development, and operational capabilities. It centralizes its talent and technology to accelerate the advancement of its CRISPR gene editing pipeline.
While Scribe Therapeutics is headquartered and primarily operates from California, USA, it establishes a global presence through strategic collaborations with major pharmaceutical companies like Sanofi and Biogen. These partnerships aim to leverage Scribe's CRISPR technologies for the development and potential commercialization of therapies worldwide, addressing global unmet medical needs.
600 West Tower Ave
Alameda
CA
USA
Address: N/A
The company's strategy appears focused on consolidating its core operations at its expansive Alameda campus to foster collaboration and efficiency.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Scribe Therapeutics' leadership includes:
Scribe Therapeutics has been backed by several prominent investors over the years, including:
Scribe Therapeutics significantly bolstered its leadership team over the past year with four key C-suite appointments, enhancing its capabilities in business development, finance, legal affairs, and human resources to support its continued growth and pipeline advancement. No prominent executive departures were publicly announced during this period.
Discover the tools Scribe Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Scribe Therapeutics likely uses common corporate email formats. Based on industry patterns and available data, the most probable format is [first_initial][last]@scribetx.com or [first].[last]@scribetx.com.
[first_initial][last]@scribetx.com
Format
boakes@scribetx.com
Example
75%
Success rate
Scribe Therapeutics Press Release • January 4, 2024
Scribe Therapeutics and Sanofi expanded their existing collaboration to include a new project leveraging Scribe’s X-Editing (XE) technologies for developing in vivo therapies. Scribe received an upfront payment and is eligible for future milestone payments and royalties....more
Scribe Therapeutics Press Release • December 5, 2023
Scribe Therapeutics announced the appointment of Sunny Chim as its new Chief Financial Officer. Mr. Chim brings over 20 years of financial leadership experience in the biopharmaceutical industry to Scribe....more
Scribe Therapeutics Press Release • October 3, 2023
Scribe Therapeutics appointed Svetlana Lucas, Ph.D., as Chief Business Officer. Dr. Lucas will lead the company's business development, corporate strategy, and alliance management functions....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Scribe Therapeutics, are just a search away.